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Patient reported outcome measures in rare
diseases: a narrative review
Anita Slade1,2,5* , Fatima Isa6, Derek Kyte1,2, Tanya Pankhurst1,3, Larissa Kerecuk1,4, James Ferguson1,3,
Graham Lipkin1,3 and Melanie Calvert1,2
Abstract
Background: Rare diseases can lead to a significant reduction in quality of life for patients and their families.
Ensuring the patients voice is central to clinical decision making is key to delivering, evaluating and understanding
the efficacy of therapeutic interventions. Patient reported outcome measures (PROMs) are used to capture the
patient’s views about their health status and facilitate our understanding of the impact of these diseases and their
treatments on patient’s quality of life and symptoms.
Main text: This review explores some of the current issues around the utilisation of PROMs in rare diseases,
including small patient populations and dearth of valid PROMs. Difficulties in validating new or current PROMs for
use in clinical trials and research are discussed. The review highlights potential solutions for some of the issues
outlined in the review and the implementation of PROMs in research and clinical practice are discussed.
Conclusion: Patient input throughout the development of PROMs including qualitative research is essential to
ensure that outcomes that matter to people living with rare disease are appropriately captured. Given the large
number of rare diseases, small numbers of patients living with each condition and the cost of instrument
development, creative and pragmatic solutions to PROM development and use may be necessary. Solutions include
qualitative interviews, modern psychometrics and resources such as item banking and computer adaptive testing.
Use of PROMs in rare disease research and clinical practice offers the potential to improve patient care and clinical
outcomes.
Keywords: Rare diseases, Rare disorders, Patient reported outcome measures, Outcome assessments, Quality of life
Background
There are approximately 7000 identified distinct rare
diseases affecting around 350 million people worldwide
[1]. In the European Union, a disease is deemed to be
rare when it affects less than 1 per 2000 persons [2]. In
the United States, a disease is defined as rare when it af-
fects fewer than 200,000 people at any given time. An
estimated 80% of rare diseases have a genetic origin and
the remaining 20% are as a result of infections (bacterial
or viral), environmental factors, allergies, proliferative
and degenerative causes [2]. Approximately 75% of rare
diseases affect children, 30% of whom die before their
5th birthday [3]. Despite this, approximately 95% of rare
diseases have no Food and Drug Administration (FDA)
approved treatment. While only 140 orphan medicines
have been authorised for use in the European Union
since 2001, and 60% of these were designated for use in
paediatric conditions [1, 4].
The challenges faced by patients with rare disease
The impact of rare diseases can be diverse and include
loss of physical function, cognitive and communication
impairments, as well as emotional problems and social
isolation. This may present challenges for patients in
their social interactions, work, and education and can
also have an adverse impact on the quality of life of
other family members [5].
Many patients with a rare disease find themselves with
unmet clinical needs due to a number of issues
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associated with access to clinical care and information
[6, 7]. Patients with the same diagnosis may present dif-
ferently because of genetic variations and timing of pre-
sentations. This can result in a delay to diagnosis, or
misdiagnosis, because they cannot access specialists with
knowledge of their disease [7, 8]. Even after receiving a
diagnosis, accessing therapeutic interventions and ap-
propriate drugs may be difficult as treatment options
maybe non existent or restricted and often costly [8, 9].
Specialist clinics are often held infrequently, are limited
in number and are located in regional centres, therefore
patients have to travel considerable distances to access
expert care [7, 9]. This can result in significant financial
burdens associated with travel costs and the need to take
time off work to undergo therapeutic procedures or
clinic visits and may prevent some patients from acces-
sing the expert care they need [8, 9]. Accessing quality
information can also be difficult for both patients and
their families because little may be known or published
about their rare disease, therefore limiting their access
to healthcare options or informed care [7, 10].
The impact of rare diseases on a patient’s daily activ-
ities means individuals are dependent on families or
carers to manage their everyday needs [3]. This loss of
autonomy can have a negative impact on their quality of
life (QoL) and has implications for their family and
carers, given the burden of care and the young age of
many of those diagnosed [2]. As a result, families have
reported psychosocial concerns and feelings of isolation
and depression [11]. The diverse presentations and pro-
gressive nature of many rare diseases make it important
to chronicle an individual’s natural history and the ex-
tent to which their health and social care needs are
changing [8].
What are patient reported outcome measures?
One way of monitoring changes in the natural history and
disease progression of a rare disease is through the use of
patient reported outcome measures (PROMs) [12, 13].
PROMs are reports directly obtained from patients about
their health status/condition or treatment without inter-
pretation by a clinician [14, 15]. PROMs are used in re-
search and clinical settings to provide the patient’s views
about a range of issues including symptom severity, func-
tion, psychological problems, treatment satisfaction and
health-related quality of life (HRQoL) [16].
PROMs are generally characterized as generic or
disease-specific measures. Generic measures are de-
signed to assess any disease condition or general popula-
tion sample. These measures can be used to compare
the health status across and between different disease
groups [12, 17]. However, generic measures may exclude
important aspects that are relevant to specific groups
[18]. Condition-specific measures are designed to assess
the severity of symptoms, or functional limitations spe-
cific to a particular health condition or diagnostic group.
Condition-specific PROMs may be more sensitive when
monitoring symptoms and detecting changes in health
within a specific homogeneous group [19].
It is also recognised that for a condition specific
PROM to have content validity it should have been de-
veloped with input from service users who have the lived
experience of the condition [19, 20]. The European
Medical Agency (EMA) [21] and the Food and Drugs
Agency (FDA) have recognised the importance of in-
cluding the patient’s perspective in development of
PROMS and the FDA guidelines state that patient input
is a requirement for applications using PROMs to sup-
port medical labelling claims [15, 22]. It has also been
demonstrated that PROMs developed using the patient’s
perspective are more robust and provide more sensitive
and specific measurements [19].
PROMs available for use in patients with rare diseases
PROMs data, if collected, analysed and reported appro-
priately, can inform shared-decision making, pharma-
ceutical labelling claims, clinical guideline development
and health policy [23]. PROMs also have an important
role as primary or secondary endpoints in clinical trials
and other epidemiological studies, developing and evalu-
ating new therapies [24]. However, there are a number
of issues relating to the use of PROMs in rare diseases.
These include: a dearth of PROMs validated for the tar-
get population, especially for children and adolescents;
sampling issues, data collection and statistical analysis
issues secondary to small sample sizes and heterogenous
study populations; and diverse contexts for recruitment
such as multi-centre international studies.
PROMs in rare disease research
Despite these issues, however, PROMs are being used to
assess the impact of rare diseases on quality of life. A
systematic review on quality of life in rare genetic
conditions concluded that the Short Form-36 item
health survey (SF-36), Cystic fibrosis questionnaire
and Dermatologic-specific QoL scales were the most
frequently used measures in primary studies [25]. An-
other review focussing on children and adolescents
with rare diseases, identified that the Child Health
and Illness Profile (CHIP), pediatric quality of life in-
ventory (PedsQL) [26] and KIDSCREEN [27] ques-
tionnaires were the measures of choice for measuring
HRQoL [25].
As well as these generic HRQoL tools, there are a num-
ber of PROMs that have been developed specifically for
rare diseases, these include: the phenylketonuria-specific
Quality-of-Life questionnaire (PKU-QoL) [28, 29]; Bird-
shot chorioretinopathy (BCR) Birdshot Disease &
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Medication Symptoms Questionnaire (BD & MSQ), qual-
ity of life impact of BCR (QoL-BCR) and the QoL impact
of BCR medication (Qol-Meds) [30]; the Kids’ ITP tool
used for children with immune thrombocytopenic pur-
pura (ITP) [31]; and the Fabry-specific Paediatric Health
and Pain Questionnaire (FPHPQ) [32].
Despite these examples, most rare diseases lack
disease-specific PROMs that can be used to gain a better
understanding of the issues that patients experience
[33]. A systematic review focussing on the impact of en-
zyme replacement therapy on HRQoL in Fabry disease
(FD) found HRQoL was lower in the FD population and
efficacy of current therapies was inconclusive [34]. They
found limitations in some of the generic HRQoL
PROMs used in the study, and suggested that a FD spe-
cific PROM would be more accurate when monitoring
patients.
Why PROMs are important in clinical practice
Routine use of PROMs in clinical practice has been
shown to improve patient satisfaction with their care,
symptom management, quality of life and survival rates
[35–37]. It may also benefit clincians by improving clin-
ician satisfaction, helping reduce burnout and increasing
workflow efficiency, as routine screening questions may
be asked in the waiting room and clinicians can use re-
sults from PROMs to inform the consultation [14]. This
can help promote patient-centred care by improving
communication between clinicians and patients about
their disease progression and the impact of prescribed
treatments [38]. PROMS can also support clinical
decision-making when prescribing therapeutic interven-
tions and managing side effects. In some specialities (e.g.
cancer, mental health), PROMs are used to assess disease
severity, monitor symptoms and responses to thera-
peutic interventions [39]. PROMs can also identify ad-
verse events and screen patients for physical and
emotional problems requiring additional clinical inter-
vention [40, 41]. While these are considerable advan-
tages, PROMs data is still not routinely collected in all
areas of clinical practice especially in the case of rare
diseases [12].
Understanding what matters to patients living with rare
diseases
In order for PROMs to be effective in clinical practice they
have to capture the disease characteristics that matter to
the patient. Selection of suitable PROMs should reflect
these properties and domains as well as reflecting the nat-
ural disease history and prognosis. This can be challenging
because of the heterogeneity of patients experiences, and
differences in presentations caused by cultural influences,
genetic and phenotype variations [42]. Therefore its im-
portant to understand these variances when establishing
key characteristics and selecting suitable PROMs. A recent
taskforce report suggested one way of identifying patient
preferences in rare diseases was through the use of quali-
tative interviews with patients, carers and their families
[12]. These could be used to elicite common core domains
and symptoms. They also suggested key areas for research
focus should include:
1) Research priorities
2) Outcomes that matter to patients (including
PROMs)
3) The views of patient and clinicians regarding the
use of PROMs in research and routine clinical
practice.
Addressing these key areas would ensure patients
voices are central to research and clinical practice. This
would enhance our understanding of the experiences of
people living with a rare disease, and help ensure that
outcomes that matter are encapsulated in research and
clinical practice. Patient Centred Outcome Measures
(PCOMs) as proposed by Morel and Cano [43] can also
provide additional benefits to health care providers by
addressing the important issues that matter to patients,
whilst providing a measure of patient benefit.
In addition to qualitative interviews other evidence to
inform PROM development may include: literature re-
views; media access, genotype-phenotype databases; ob-
servational studies; case histories; rare disease registries;
and observer information e.g. parents and carers [12].
Access to patient forums and blogs may also help re-
searchers to gain insights into the issues that matter to
patients [44]. Patient and public involvement (PPI), and
patient advocacy groups also present additional opportun-
ities for accessing patients’ viewpoints [45, 46]. Encapsu-
lating patients viewpoints into PROMs and collaborations
between industry, academics and patient partners can im-
prove the quality of data collected [47–49]. As demon-
strated by Mesa et al. [48] who identified which symptoms
were important to patients with myelofibrosis (a rare mye-
loproliferative neoplasm) through qualitative interviews.
They used this information to create and test an appropri-
ate PROM for use in a clinical trial of ruxolitinib [50].
Using a PROM that was meaningful to the patients re-
sulted in more than 95% compliance in the trial and the
results demonstrated that the experimental group had a
50% or greater improvement in comparison to the control
group [47]. This resulted in approval of ruxolitinib by the
FDA and EMA [47].
Using PROMs in patient registries
Patient registries are also a useful tool for the develop-
ment of rare disease research and can help improve pa-
tient care and services, as well as development of new
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treatments [2, 51]. Rare disease registries have often
grown organically and are usually initiated by organisa-
tions including patients, family, carers and advocacy
groups, as well as industry partners, health services and
clinicians [52]. Registries are important resources for in-
formation on the natural history of diseases, supporting
enrollment of patients to research and to assess the im-
pact of new therapies in real-world settings [51]. PROMs
are increasingly being used in patient registries to under-
stand the patient perspective and disease management
strategies [53].Incorporation of PROMs in registries can
improve our understanding of the impact of symptoms
and QoL over the course of the disease and treatment
[52]. There are a large number of registries for rare dis-
eases and and a number of them are collecting PROM
data [54]. Examples of these registries can be found on-
line, including the UK Cystic Fibrosis registry [55] and
the Cystic Fibrosis Foundation United States (US) [56].
The lysosomal storage disorder registry is also an ex-
ample of how conditions with a common link can be
accomodated together e.g. Fabry disease, [57] Pompe
[58] and Gaucher [59]. This approach allows common
themes to be identified and pools resources for families,
clinicians and researchers.
Proms for assessing service delivery
As well as being an important tool in clinical care
PROMs can be used to evaluate service delivery as dem-
onstrated by the use of the EQ-5D for audit/benchmark-
ing purposes in the UK National Health Service (NHS)
since 2009. The EQ-5D in conjunction with disease spe-
cific measures are used to measure HRQoL change pre
and post-surgery in Hip and knee replacements, hernia
repairs and varicose vein surgery [60, 61]. PROM data
collected at a national level in this way can inform pa-
tients’ decisions regarding the selection of their pre-
ferred health care provider. However such an approach
is not without challenges, for example reducing levels of
missing data and providing information on PROM re-
sults to patients in an easily accessible way can be diffi-
cult to achieve [62, 63]. Using PROMs as part of routine
care would give patients an important say in their treat-
ment and could be used as a performance metric to
compare the quality and effectiveness of care providers.
This is especially important given the complexities asso-
ciated with their care pathways and dearth of specialist
services [64].
The diversity of PROMs currently used in clinical trials
and practice makes it difficult to compare results when
different outcomes have been utilised. Consequently, there
have been moves to develop recommended core outcome
measures for different conditions for use in clinical trials
and service evaluation. This approach has been developed
by the International Consortium for Health Outcomes
Measurement (ICHOM), their remit is to incorporate pa-
tient and clinician view points and develop standardised
sets of outcome measures for specific medical conditions
based on concerns that matter to patients, these can then
be used to evaluate and compare services [65]. Other ap-
proaches to developing core outcome sets include those
developed by Core Outcome Measures in Effectiveness
Trials (COMET) which brings together experts and re-
searchers in specific conditions to develop core outcome
sets recommended for use in trials and clinical practice.
Another group taking a similar route includes the Out-
come Measures in Rheumatology (OMERACT) initiative
which also aims to develop a consensus on which out-
come measures should be used in autoimmune and mus-
culoskeletal conditions [66].
Selecting reliable and valid PROMS
Having identified which issues matter most to patients it
then becomes important to ensure that selection of poten-
tial PROMs reflects those issues. Additional consider-
ations include the psychometric validity of the PROM and
the context in which PROM data are being collected. En-
suring the reliability, validity and acceptability of the
measure is a crucial component of selecting PROMs for
use in rare diseases. Evaluating the measurement proper-
ties of PROMs in rare disease is challenging because of
the small numbers of patients and heterogenous popula-
tions. Therefore, some of the usual options for choosing,
adapting or developing PROMs are not always appropriate
or available for this group of patients and may require
adaptation [12]. Key to this process is understanding the
construct of interest (COI) and a clearly defined rationale
for using PROMs within a research study in order to reach
a meaningful conclusion about the outcome/endpoints
that will be measured [67]. When deciding on the PROM
to use, the COI should meet the aim of the research study
e.g. symptom burden, or HRQoL [67]. Additionally, the
measure should be selected according to the population of
interest e.g. disease characteristics. Information gleaned
from qualitative interviews on which symptoms and out-
comes are important to the patients can inform this
process. However, given the challenges of recruitment in
rare diseases it may be more pragmatic to use existing
measures with additional items to capture specific disease
issues or domains [12].
A systematic review may be required to identify the
most suitable PROMs [67]. Guidelines developed by the
COnsensus-based Standards for the selection of health
Measurement INstruments (COSMIN) initiative aims to
help improve the selection of outcome measurement for
research and clinical practice [68]. This has included the
development of a critical appraisal tool for evaluating
the methodological quality of studies evaluating health
measures such as PROMs. Systematic reviews can be
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used as tools to identify gaps in knowledge on the qual-
ity/measurement properties of PROMs or potential
PROMs for use in rare diseases [69]. An example of how
COSMIN guidelines can be used in practice is demon-
strated in a systematic review of PROMs used in Primary
Sclerosing Cholangitis (PSC), conducted by the authors.
The review found that a wide diversity of PROMs were
used to measure HRQoL and symptom burden in pa-
tients with PSC. However, the quality of the evidence to
support reliability and validity in the most commonly
used measures was generally poor and only one had
been validated within this population following FDA
guidelines [70, 71].
Additional sources of information include databases such
as ePROVIDE™ which has a range of information on
PROMs and includes some critical review on the measure-
ment properties for each PROM [72]. Additional databases
include the Patient-Reported Outcomes Measurement In-
formation System (PROMIS) which is a co-operative group
program of research which aims to develop, validate and
standardise item banks to capture PROM data across a
wide range of conditions and domains for use in a range of
chronic disorders and conditions [73].
PROMIS uses item response theory (IRT) and com-
puter adaptive testing (CAT) technology to generate and
validate item banks for specific domains [74]. Access to
electronic forms of data collection using different psy-
chometric models offer some potential solutions to the
issues that arise from using traditional methods such as
classical test theory (CTT). These models include IRT,
and Rasch measurement theory (RMT). Increasingly
these different methods are being used to modify or
evaluate PROMs for use in rare diseases [43, 75].
While it is important to collect a comprehensive range
of information using PROMs often data includes a wide
range of domains. Collecting information on every PROM
for every domain can be burdensome and result in PROM
fatigue and missing data. CAT technology is effective in
reducing this burden, by only presenting a small but spe-
cific number of questions, sequentially selected based on
responses to previous questions [74]. This approach also
means that condition specific items as highlighted by the
patients living with the rare disease can be incorporated
with readily available tools [76]. This allows tailoring of
the PROM to a patient’s specific symptoms or needs with-
out the need to develop a completely new instrument.
One of the drawbacks of this method are the large sample
sizes required to carry out psychometric analysis for valid-
ation of the PROMs [77]. Using RMT is a potential solu-
tion to this issue. Rare group populations can be
combined with populations with similar disease presenta-
tions [78, 79]. Examination of differential item functioning
(DIF) analysis by diagnostic group could identify if re-
sponses from these groups are equivocal, if they are then
both samples can be used to validate PROMs [80]. Items
where DIF is an issue can be split and used with the ap-
propriate population in an item bank.
Mattera et al. [76] used concept elicitation and cogni-
tive interviews to refine potential items from the PRO-
MIS physical function (PF) item bank for use with
patients with Fibrodysplasia Ossificans Progressiva
(FOP) (an ultra-rare and progressive disease). Concept
elicitation interviews were used to identify the impact of
FOP on daily life and the concepts that mattered to the
participants living with FOP. Themes and concepts from
the interviews were identified and items that reflected
these were established from the selected PROMIS PF
items. Cognitive interviews were used to ensure that se-
lected items were relevant and understood by the partic-
ipants. The findings of the study demonstrated that
concept elicitation and cognitive interviews could sup-
port development or modification of instruments for use
with rare diseases [76].
Cultural adaptation of PROMS
While pooling data maybe one option, participants re-
cruited for clinical trials might not only be recruited from
multiple-centres but also different countries [75]. Therefore
PROMs will be required in different languages in order to
accommodate this type of rescruitiment. This raises a num-
ber of issues. Firstly, PROMs should have been translated
using industry standard methods, as both language and cul-
tural adaptations are required [12]. Cultural adaptation en-
sures that the context and content is appropriate for the
population. This aspect of translation is often overlooked
when translating PROMs and this can have a negative im-
pact on attrition rates and levels of missing data. There are
a number of recommendations for adapting PROMs to en-
sure cross cultural validity and equivalence [81–83]. Pool-
ing data from international studies maybe the only way of
recruiting sufficient sample sizes to test the psychometric
properties of a PROM or to establish suitable therapeutic
interventions. However, because of the influences of cul-
tural adaptations it then becomes important to ensure the
cross-cultural validity and equivalence of PROMs before
pooling data. One approach to doing this could be through
the use of RMT. By using RMT it is possible to establish
whether DIF by country or language is an issue [84]. If DIF
by country is not identified then cross-cultural equivalence
can be assumed and pooled data results can be utilised in
clinical trials [84]. Regnault and Herdman (2015) also sug-
gest using factor analysis and the Universalist model to es-
tablish whether the theoretical model fits the data.
Confirmatory factor analysis and qualitative interviews are
used to evaluate conceptual and cross cultural equivalence
of PROMs [83]. Utilising psychometric methods alongside
qualitative methods can facilitate identification of the most
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appropriate PROMs for use in rare diseases and conditions
of interest [85].
Technological advances and prom data collection
The rapid progression of alternative technologies, in-
creased connectivity and ease of administration has seen
the increasing use of electronic PROMs (ePROMs),
allowing data to be collected internationally, locally and
in real time. It also gives patients the freedom to
complete PROMs using an electronic device of their
choosing e.g. tablets, smartphones etc. and at a time that
is convenient for them [86]. This is particularly import-
ant for patients with unstable conditions or high symp-
tom burden who are likely to deteriorate rapidly [86].
Patients can also opt to complete PROMs prior to clin-
ical visits [36]. Technological advances also offer alterna-
tive and adaptive methods for data collection such as
audio options for people with low vision and touch
screens that eliminate the need for computer skills [36].
Wearable technology and Telehealth are used to capture
clinical data, allowing patients remote access to expert
clinical care without the need for expensive travel. In-
corporating PROM data capture in addition to clinical
data would allow clinicians to evaluate the health status
of patients between clinic appointments and monitor the
impact or side effects of drug from therapeutic interven-
tions [87, 88].
PROMs can be integrated into electronic healthcare
records and the use of predetermined threshold absolute
and change scores can generate an automatic notifica-
tion that can be provided both to the patient and the
clinical team where follow-up is required [36]. Appoint-
ments can be changed if patients appear to be deterior-
iating or postponed if patients appear stable. Thereby
improving access to timely health care interventions
while reducing patients’ health and financial burdens, re-
ducing service costs by utilising health service resources
appropriately [35]. The Patient-Centred Outcomes Re-
search Institute (PCORI) have developed a comprehen-
sive guide on how to integrate ePROMS into electronic
health records [89].
This paper has highlighted some of the issues that
have been identified in using PROMs in rare diseases,
however, they are not insurmountable and we have of-
fered a number of potential solutions. Identifying the is-
sues for people living with rare diseases and ensuring
that their views are central to health care and policy is
paramount. It is also important to remember that having
an appropriate PROM in place does not necessarily
mean that data can be collected from all patients. Phys-
ical limitations, cognitive impairments and age may pre-
vent some patients from completing the PROM. In these
instances, alternate methods such as interviews or obser-
ver collected data maybe required to enable completion.
The International Society for Pharmoeconomics and
Outcomes Research (ISPOR) has recently published
comprehensive guidance on how this can be achieved
[12]. There is also an increasing emphasis on integrating
quality PROM data into clinical care enabling dialogue
between the clinician and patients and facilitating joint
decision making around care options. In some respects
this is more important for patients with rare diseases,
than other long-term conditions as often their voices are
in the minority and their clinical options limited. The
use of PROMs potentially provides a more complete pic-
ture of their experiences and enables better communica-
tion with the clinical team.
Conclusion
Rare diseases can be chronically debilitating or life-
threatening conditions, leading to a significant reduction
in QoL for both the patient and their families. Small pa-
tient populations and a relative scarcity of medical
knowledge and specialists in rare diseases make it chal-
lenging to understand the burden of these diseases in
patients. The importance of ensuring that the patients
voice is central to clinical decision making is key to de-
livering, evaluating and understanding therapeutic inter-
ventions. However, this requires ways of evaluating
outcomes that reflect patients needs and concerns as
well as clinically driven measures and outcomes. The
dearth of valid PROMs for use in many rare conditions
and difficulties in validating currently available PROMs
makes evaluating effective treatments problematic. Pa-
tient input throughout the development of PROMs in-
cluding qualitative research is essential to ensure that
outcomes that matter to people living with rare disease
are appropriately captured. Given the large number of
rare diseases, small numbers of patients living with each
condition and the cost of instrument development, cre-
ative and pragmatic solutions to PROM development
and use may be necessary, such as the development of
item banks and use of CAT. Use of PROMs in rare dis-
ease research and clinical practice offers the potential to
improve patient care and outcomes.
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